A study to investigate the safety and efficacy of IOV-3001 in adults with advanced (unresectable or metastatic) melanoma who will receive lifileucel

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel